Income Statement GlycoNex Incorporation

Stocks

4168

TW0004168000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 2026-07-17			5-day change	1st Jan Change
23.45 ^TWD	-2.09%		-6.94%	-8.93%

06-10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

d6307e211e1444488c6e6d6ecbb.uty-dQ_lDUZD08Q1HhyYo15R4FV7FM4utR4aO4Tl_k8.2bryI2zVXgwNhb59U3va9GgFhDEiTP5U71tqafKUkirRk843OqpUCXuqgQ

Published financial data: GLYCONEX INCORPORATION

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	5.48M	30.08M	2.54M	14.7M	37.86M
Total Revenues	5.48M	30.08M	2.54M	14.7M	37.86M
Cost of Goods Sold, Total	2.01M	16.12M	1.55M	7.38M	14.35M
Gross Profit	3.46M	13.97M	995K	7.32M	23.51M
Selling General & Admin Expenses, Total	53.38M	55.2M	50.48M	48.88M	50.94M
Provision for Bad Debts	-	307K	-	-	-
R&D Expenses	145M	197M	210M	205M	222M
Other Operating Expenses, Total	198M	253M	261M	253M	273M
Operating Income	-195M	-239M	-260M	-246M	-250M
Interest Expense, Total	-	-2.75M	-3.63M	-3.63M	-4.49M
Interest And Investment Income	2.74M	4.59M	9.37M	8.1M	5.7M
Net Interest Expenses	2.74M	1.84M	5.74M	4.46M	1.21M
Currency Exchange Gains (Loss)	-1.07M	-480K	-551K	3.46M	3.61M
Other Non Operating Income (Expenses)	20.77M	17.76M	17.15M	8.51M	10.86M
EBT, Excl. Unusual Items	-172M	-220M	-238M	-230M	-234M
Gain (Loss) On Sale Of Investments	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	73.81M	-	-
Asset Writedown	-	-	-	-	-
EBT, Incl. Unusual Items	-172M	-220M	-164M	-230M	-234M
Income Tax Expense	-	-	14.64M	24K	1.09M
Earnings From Continuing Operations	-172M	-220M	-178M	-230M	-235M
Net Income to Company	-172M	-220M	-178M	-230M	-235M
Net Income - (IS)	-172M	-220M	-178M	-230M	-235M
Net Income to Common Incl Extra Items	-172M	-220M	-178M	-230M	-235M
Net Income to Common Excl. Extra Items	-172M	-220M	-178M	-230M	-235M
Per Share Items
Net EPS - Basic	-1.78	-2.21	-1.65	-2.12	-2.16
Basic EPS - Continuing Operations	-1.78	-2.21	-1.65	-2.12	-2.16
Basic Weighted Average Shares Outstanding	97.04M	99.46M	108M	108M	109M
Net EPS - Diluted	-1.78	-2.21	-1.65	-2.12	-2.16
Diluted EPS - Continuing Operations	-1.78	-2.21	-1.65	-2.12	-2.16
Diluted Weighted Average Shares Outstanding	97.04M	99.46M	108M	108M	109M
Normalized Basic EPS	-1.11	-1.38	-1.38	-1.33	-1.34
Normalized Diluted EPS	-1.11	-1.38	-1.38	-1.33	-1.34
Supplemental Items
EBITDA	-165M	-199M	-229M	-212M	-214M
EBITA	-195M	-238M	-258M	-246M	-249M
EBIT	-195M	-239M	-260M	-246M	-250M
Effective Tax Rate - (Ratio)	-	-	-8.95	-0.01	-0.47
Current Domestic Taxes	-	-	-	-	-
Total Current Taxes	-	-	14.64M	24K	1.09M
Deferred Domestic Taxes	-	-	-	-	-
Total Deferred Taxes	-	-	-	-	-
Normalized Net Income	-108M	-137M	-148M	-144M	-146M
Interest on Long-Term Debt	-	2.72M	3.62M	3.63M	4.49M
Non-Cash Pension Expense	16K	38K	50K	46K	51K
Supplemental Operating Expense Items
Selling and Marketing Expenses	4.53M	4.42M	5.21M	4.38M	5.35M
General and Administrative Expenses	48.85M	50.78M	45.27M	44.5M	45.59M
Research And Development Expense From Footnotes	145M	197M	210M	205M	222M
Stock-Based Comp., Other (Total)	-2.83M	3.34M	-	-	265K
Total Stock-Based Compensation	-2.83M	3.34M	-	-	265K

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	125M	82.19M	149M	110M	468M
Short Term Investments	207M	597M	550M	333M	226M
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	332M	679M	700M	442M	693M
Accounts Receivable, Total	350K	46K	25K	-	2.22M
Other Receivables	4.73M	8.8M	7.67M	34.48M	48.64M
Total Receivables	5.08M	8.84M	7.7M	34.48M	50.86M
Prepaid Expenses	21.88M	25.2M	9.73M	4.3M	3.5M
Other Current Assets, Total	140K	310K	1.13M	316K	435K
Total Current Assets	359M	713M	718M	481M	748M
Gross Property Plant And Equipment	1.28B	1.29B	1.11B	1.15B	1.15B
Accumulated Depreciation	-260M	-299M	-297M	-329M	-362M
Net Property Plant And Equipment	1.02B	990M	814M	819M	790M
Long-term Investments	14.2M	13.52M	12.61M	12.04M	9.66M
Other Intangibles, Total	-	-	-	3.76M	5.21M
Deferred Tax Assets Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	174K	384K	8.22M	657K	1.14M
Total Assets	1.4B	1.72B	1.55B	1.32B	1.55B
Liabilities
Accounts Payable, Total	900K	900K	900K	900K	900K
Accrued Expenses, Total	20.45M	32.84M	36.35M	28.68M	70.63M
Short-term Borrowings	-	5M	-	-	-
Current Income Taxes Payable	-	-	14.64M	-	-
Unearned Revenue Current, Total	76K	76K	104K	14.16M	15.34M
Other Current Liabilities	5.78M	5.67M	219M	221M	6.62M
Total Current Liabilities	27.21M	44.48M	271M	265M	93.49M
Long-Term Debt	-	219M	-	-	474M
Pension & Other Post Retirement Benefits	5.44M	4.19M	3.83M	3.37M	2.8M
Deferred Tax Liability Non Current	-	-	-	-	-
Other Non Current Liabilities	3.42M	3.98M	1.98M	2M	2.01M
Total Liabilities	36.07M	271M	276M	270M	572M
Common Stock, Total	975M	1.07B	1.09B	1.09B	1.13B
Additional Paid In Capital	564M	587M	375M	197M	159M
Retained Earnings	-173M	-219M	-178M	-229M	-291M
Treasury Stock	-	-	-	-	-
Comprehensive Income and Other	-6.87M	5.86M	-6.73M	-7.3M	-10.84M
Total Common Equity	1.36B	1.45B	1.28B	1.05B	982M
Total Equity	1.36B	1.45B	1.28B	1.05B	982M
Total Liabilities And Equity	1.4B	1.72B	1.55B	1.32B	1.55B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	97.48M	107M	109M	108M	113M
ECS Total Common Shares Outstanding	97.48M	107M	109M	108M	113M
Book Value / Share	13.94	13.5	11.75	9.67	8.73
Tangible Book Value	1.36B	1.45B	1.28B	1.04B	977M
Tangible Book Value Per Share	13.94	13.5	11.75	9.64	8.68
Total Debt	0	224M	0	0	474M
Net Debt	-332M	-455M	-700M	-442M	-220M
Debt Equivalent of Unfunded Proj. Benefit Obligation	5.44M	4.19M	3.83M	3.37M	2.81M
Account Code - Inventory Valuation	3	3	3	3	3
Land - (BS)	142M	142M	142M	142M	142M
Buildings, Total	391M	391M	391M	391M	391M
Machinery, Total	142M	149M	160M	197M	201M
Assets on Operating Lease - Gross	608M	608M	419M	419M	419M
Assets on Operating Lease - Accumulated Depreciation	-56.75M	-66.88M	-48.37M	-54.1M	-59.83M

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-172M	-220M	-178M	-230M	-235M
Depreciation & Amortization - CF	39.8M	39.34M	29.81M	34.13M	34.87M
Amortization of Goodwill and Intangible Assets - (CF)	328K	619K	1.37M	244K	550K
Depreciation & Amortization, Total	40.13M	39.96M	31.18M	34.37M	35.42M
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	-	-	-73.81M	-	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	-	-
Stock-Based Compensation (CF)	-2.83M	3.34M	-	-	265K
Provision and Write-off of Bad Debts	-	307K	-	-	-
Other Operating Activities, Total	126K	2.42M	18.03M	-17.95M	4.08M
Change in Trading Asset Securities	-	-	-	-	-
Change In Accounts Receivable	-334K	304K	21K	25K	-2.22M
Change In Accounts Payable	1.64M	13.66M	2.86M	-8.12M	43.64M
Change in Unearned Revenues	-219K	-	28K	14.06M	1.18M
Change In Income Taxes	-	-	-	-	-
Change in Other Net Operating Assets	-7.11M	-7.72M	16.13M	-14.66M	-13.42M
Cash from Operations	-141M	-168M	-184M	-222M	-166M
Capital Expenditure	-6.84M	-8.69M	-23.42M	-31.28M	-4.58M
Sale of Property, Plant, and Equipment	-	-	237M	-	-
Sale (Purchase) of Real Estate properties	-	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-4M	-2M
Investment in Marketable and Equity Securities, Total	120M	-390M	46.27M	218M	107M
Other Investing Activities, Total	-35K	-829K	-2.39M	-435K	-1.7M
Cash from Investing	113M	-400M	258M	182M	98.72M
Short Term Debt Issued, Total	-	66M	10M	-	-
Long-Term Debt Issued, Total	-	421M	-	-	546M
Total Debt Issued	-	487M	10M	-	546M
Short Term Debt Repaid, Total	-	-61M	-15M	-	-
Long-Term Debt Repaid, Total	-	-	-	-	-168M
Total Debt Repaid	-	-61M	-15M	-	-168M
Issuance of Common Stock	-	104M	-	-	53.75M
Repurchase of Common Stock	-	-	-	-	-
Other Financing Activities, Total	-27K	-4.89M	-1.72M	12K	-5.28M
Cash from Financing	-27K	524M	-6.72M	12K	426M
Net Change in Cash	-27.67M	-42.88M	67.28M	-39.96M	358M
Supplemental Items
Cash Interest Paid	-	1.64M	2.09M	2.08M	2.55M
Cash Income Tax Paid (Refund)	-106K	-87K	44K	21.84M	1.23M
Levered Free Cash Flow	-96.62M	-111M	89.98M	-183M	-317M
Unlevered Free Cash Flow	-96.62M	-110M	92.24M	-181M	-314M
Change In Net Working Capital	5.26M	-5.02M	-247M	26.48M	187M
Net Debt Issued / Repaid	-	426M	-5M	-	377M

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-8.21	-9.6	-9.93	-10.72	-10.88
Return on Total Capital	-8.41	-9.86	-11.03	-13.24	-12.48
Return On Equity %	-11.9	-15.68	-13.1	-19.78	-23.19
Return on Common Equity	-11.9	-15.68	-13.1	-19.78	-23.19
Margin Analysis
Gross Profit Margin %	63.21	46.43	39.14	49.8	62.1
SG&A Margin	975.01	183.48	1.99K	332.53	134.55
EBITDA Margin %	-3.01K	-661.43	-9K	-1.44K	-566.24
EBITA Margin %	-3.55K	-792.19	-10.17K	-1.67K	-658.35
EBIT Margin %	-3.56K	-794.24	-10.22K	-1.67K	-659.81
Income From Continuing Operations Margin %	-3.15K	-730.67	-7.02K	-1.56K	-621.29
Net Income Margin %	-3.15K	-730.67	-7.02K	-1.56K	-621.29
Net Avail. For Common Margin %	-3.15K	-730.67	-7.02K	-1.56K	-621.29
Normalized Net Income Margin	-1.97K	-456.67	-5.84K	-976.47	-386.5
Levered Free Cash Flow Margin	-1.76K	-370.4	3.54K	-1.25K	-836.38
Unlevered Free Cash Flow Margin	-1.76K	-364.69	3.63K	-1.23K	-828.97
Asset Turnover
Asset Turnover	0	0.02	0	0.01	0.03
Fixed Assets Turnover	0.01	0.03	0	0.02	0.05
Receivables Turnover (Average Receivables)	29.92	151.94	71.61	-	-
Short Term Liquidity
Current Ratio	13.18	16.03	2.65	1.82	8
Quick Ratio	12.37	15.46	2.61	1.8	7.96
Operating Cash Flow to Current Liabilities	-5.19	-3.77	-0.68	-0.84	-1.78
Days Sales Outstanding (Average Receivables)	12.2	2.4	5.1	-	-
Average Days Payable Outstanding	163.11	20.38	212.35	44.63	22.89
Long Term Solvency
Total Debt/Equity	-	15.47	-	-	48.21
Total Debt / Total Capital	-	13.4	-	-	32.53
LT Debt/Equity	-	15.13	-	-	48.21
Long-Term Debt / Total Capital	-	13.1	-	-	32.53
Total Liabilities / Total Assets	2.59	15.8	17.8	20.51	36.79
EBIT / Interest Expense	-	-86.95	-71.67	-67.74	-55.65
EBITDA / Interest Expense	-	-72.41	-63.07	-58.28	-47.76
(EBITDA - Capex) / Interest Expense	-	-75.58	-69.53	-66.89	-48.78
Total Debt / EBITDA	-	-1.12	-	-	-2.21
Net Debt / EBITDA	2.14	2.29	3.06	2.09	1.02
Total Debt / (EBITDA - Capex)	-	-1.08	-	-	-2.16
Net Debt / (EBITDA - Capex)	2.05	2.19	2.78	1.82	1
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	1.11K	449.5	-91.55	478.32	157.54
Gross Profit, 1 Yr. Growth %	2.67K	303.55	-92.88	635.78	221.16
EBITDA, 1 Yr. Growth %	-7.17	28.55	14.92	-7.41	1.25
EBITA, 1 Yr. Growth %	-6.6	22.47	8.46	-5.38	1.38
EBIT, 1 Yr. Growth %	-8.96	22.58	8.75	-5.29	1.5
Earnings From Cont. Operations, 1 Yr. Growth %	6	27.44	-18.86	28.79	2.4
Net Income, 1 Yr. Growth %	6	27.44	-18.86	28.79	2.4
Normalized Net Income, 1 Yr. Growth %	-10.81	27.44	8.06	-3.3	1.94
Diluted EPS Before Extra, 1 Yr. Growth %	-2.84	24.17	-25.16	28.34	1.85
Accounts Receivable, 1 Yr. Growth %	2.09K	-86.86	-45.65	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-3.1	-3.13	-17.81	0.64	-3.5
Total Assets, 1 Yr. Growth %	-11.37	23.08	-9.56	-15.22	18.06
Tangible Book Value, 1 Yr. Growth %	-11.73	6.38	-11.7	-18.31	-6.29
Common Equity, 1 Yr. Growth %	-11.73	6.38	-11.7	-18.01	-6.13
Cash From Operations, 1 Yr. Growth %	-3.1	18.95	9.77	20.69	-25.09
Capital Expenditures, 1 Yr. Growth %	265.33	27.05	169.54	33.54	-85.37
Levered Free Cash Flow, 1 Yr. Growth %	8.49	15.33	-180.74	-303.92	72.59
Unlevered Free Cash Flow, 1 Yr. Growth %	9.63	13.55	-184.07	-296.45	73.2
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	173.11	716.75	-31.86	-30.1	285.93
Gross Profit, 2 Yr. CAGR %	381.96	957.05	-46.38	-27.6	386.11
EBITDA, 2 Yr. CAGR %	-12.57	5.83	21.55	3.15	-3.18
EBITA, 2 Yr. CAGR %	-13.27	6.95	15.25	1.57	-2.06
EBIT, 2 Yr. CAGR %	-15.01	5.64	15.46	1.49	-1.95
Earnings From Cont. Operations, 2 Yr. CAGR %	-16.47	16.23	1.69	2.22	14.84
Net Income, 2 Yr. CAGR %	-16.47	16.23	1.69	2.22	14.84
Normalized Net Income, 2 Yr. CAGR %	-16.38	6.61	17.35	2.22	-0.72
Diluted EPS Before Extra, 2 Yr. CAGR %	-26.11	9.84	-3.6	-2	14.33
Accounts Receivable, 2 Yr. CAGR %	-	69.56	-73.27	-	843.4
Net Property, Plant and Equip., 2 Yr. CAGR %	-3.22	-3.12	-10.77	-9.05	-1.45
Total Assets, 2 Yr. CAGR %	2.33	4.44	5.5	-12.44	0.05
Tangible Book Value, 2 Yr. CAGR %	2.41	-3.1	-3.08	-15.07	-12.51
Common Equity, 2 Yr. CAGR %	2.21	-3.1	-3.08	-14.92	-12.27
Cash From Operations, 2 Yr. CAGR %	-11.37	7.28	14.27	15.1	-4.92
Capital Expenditures, 2 Yr. CAGR %	113.81	115.44	85.05	89.72	-55.8
Levered Free Cash Flow, 2 Yr. CAGR %	-3.3	11.86	-3.5	28.32	87.6
Unlevered Free Cash Flow, 2 Yr. CAGR %	-3.3	11.57	-2.29	28.51	84.46
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	80.82	244.79	77.96	38.99	7.96
Gross Profit, 3 Yr. CAGR %	93.46	354.26	99.67	28.37	18.96
EBITDA, 3 Yr. CAGR %	-14.7	-2.66	8.78	11.01	2.51
EBITA, 3 Yr. CAGR %	-14.39	-2.7	7.45	8.11	1.51
EBIT, 3 Yr. CAGR %	-15.37	-3.97	6.67	8.08	1.49
Earnings From Cont. Operations, 3 Yr. CAGR %	-18.35	-3.84	3.1	10.02	2.28
Net Income, 3 Yr. CAGR %	-18.35	-3.84	3.1	10.02	2.28
Normalized Net Income, 3 Yr. CAGR %	-16.86	-3.77	7.09	10.01	2.12
Diluted EPS Before Extra, 3 Yr. CAGR %	-24.79	-12.15	-3.35	6.05	-0.73
Accounts Receivable, 3 Yr. CAGR %	132.08	-	16.04	-	264.35
Net Property, Plant and Equip., 3 Yr. CAGR %	-3.34	-3.19	-8.28	-7.12	-7.24
Total Assets, 3 Yr. CAGR %	-3.69	8.82	-0.45	-1.91	-3.26
Tangible Book Value, 3 Yr. CAGR %	-3.58	3.72	-6.06	-8.45	-12.24
Common Equity, 3 Yr. CAGR %	-3.93	3.58	-6.06	-8.34	-12.08
Cash From Operations, 3 Yr. CAGR %	-7.86	-2.28	8.1	16.37	-0.25
Capital Expenditures, 3 Yr. CAGR %	28.54	79.75	132.15	65.99	-19.25
Levered Free Cash Flow, 3 Yr. CAGR %	-10.63	2.55	0.34	23.83	41.64
Unlevered Free Cash Flow, 3 Yr. CAGR %	-10.63	2.02	1.53	23.32	41.96
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	87.07	116.4	22.38	82.11	142.55
Gross Profit, 5 Yr. CAGR %	89.67	116.3	15.79	117.91	185.02
EBITDA, 5 Yr. CAGR %	19.09	12.89	-2.96	-0.38	3.83
EBITA, 5 Yr. CAGR %	15.69	9.63	-3.58	-1.01	3.65
EBIT, 5 Yr. CAGR %	13.34	8.24	-4.17	-1.83	3.13
Earnings From Cont. Operations, 5 Yr. CAGR %	12.11	8.74	-10.86	-1.46	7.65
Net Income, 5 Yr. CAGR %	12.11	8.74	-10.86	-1.46	7.65
Normalized Net Income, 5 Yr. CAGR %	11.71	8.59	-4.57	-1.42	3.9
Diluted EPS Before Extra, 5 Yr. CAGR %	6.65	2.92	-16.94	-8.22	3.37
Accounts Receivable, 5 Yr. CAGR %	-6.55	-25.47	-2.24	-	168.31
Net Property, Plant and Equip., 5 Yr. CAGR %	-0.03	-3.3	-6.38	-5.58	-5.61
Total Assets, 5 Yr. CAGR %	-7.29	-1.66	-0.12	-0.24	-0.25
Tangible Book Value, 5 Yr. CAGR %	-6.77	-4.24	-3.38	-4.25	-8.69
Common Equity, 5 Yr. CAGR %	-7.31	-4.72	-3.59	-4.26	-8.59
Cash From Operations, 5 Yr. CAGR %	5.46	22.22	0.39	4.33	2.69
Capital Expenditures, 5 Yr. CAGR %	-42.46	-48.32	48.71	83.68	19.57
Levered Free Cash Flow, 5 Yr. CAGR %	-9.6	-19.41	-7.84	12.17	28.88
Unlevered Free Cash Flow, 5 Yr. CAGR %	-9.54	-19.64	-7.38	11.89	28.92